UIPATH INC - CLASS A (PATH)

US90364P1057 - Common Stock

22.67  -0.11 (-0.48%)

After market: 22.7096 +0.04 (+0.17%)

Fundamental Rating

5

Taking everything into account, PATH scores 5 out of 10 in our fundamental rating. PATH was compared to 279 industry peers in the Software industry. PATH has a great financial health rating, but its profitability evaluates not so good. PATH is valied quite expensively at the moment, while it does show a decent growth rate.



3

1. Profitability

1.1 Basic Checks

PATH had positive earnings in the past year.
In the past year PATH had a positive cash flow from operations.
In the past 5 years PATH always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: PATH reported negative operating cash flow in multiple years.

1.2 Ratios

With a decent Return On Assets value of -3.04%, PATH is doing good in the industry, outperforming 63.31% of the companies in the same industry.
The Return On Equity of PATH (-4.46%) is better than 67.27% of its industry peers.
Industry RankSector Rank
ROA -3.04%
ROE -4.46%
ROIC N/A
ROA(3y)-11.83%
ROA(5y)-29.69%
ROE(3y)-16.3%
ROE(5y)-67.01%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of PATH (85.04%) is better than 92.45% of its industry peers.
PATH's Gross Margin has improved in the last couple of years.
PATH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 85.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.58%
GM growth 5Y3.54%

8

2. Health

2.1 Basic Checks

PATH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PATH has more shares outstanding
There is no outstanding debt for PATH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 8.32 indicates that PATH is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 8.32, PATH belongs to the top of the industry, outperforming 82.73% of the companies in the same industry.
There is no outstanding debt for PATH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 8.32
ROIC/WACCN/A
WACC9.35%

2.3 Liquidity

A Current Ratio of 3.63 indicates that PATH has no problem at all paying its short term obligations.
PATH has a Current ratio of 3.63. This is in the better half of the industry: PATH outperforms 79.86% of its industry peers.
PATH has a Quick Ratio of 3.63. This indicates that PATH is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 3.63, PATH belongs to the best of the industry, outperforming 80.22% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.63
Quick Ratio 3.63

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 260.00% over the past year.
Looking at the last year, PATH shows a very strong growth in Revenue. The Revenue has grown by 23.58%.
Measured over the past years, PATH shows a very strong growth in Revenue. The Revenue has been growing by 54.52% on average per year.
EPS 1Y (TTM)260%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q46.67%
Revenue 1Y (TTM)23.58%
Revenue growth 3Y29.12%
Revenue growth 5Y54.52%
Revenue growth Q2Q31.36%

3.2 Future

PATH is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.74% yearly.
The Revenue is expected to grow by 12.48% on average over the next years. This is quite good.
EPS Next Y0.21%
EPS Next 2Y13.24%
EPS Next 3Y9.23%
EPS Next 5Y-0.74%
Revenue Next Year19.05%
Revenue Next 2Y18.33%
Revenue Next 3Y16.79%
Revenue Next 5Y12.48%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

2

4. Valuation

4.1 Price/Earnings Ratio

PATH is valuated quite expensively with a Price/Earnings ratio of 41.98.
Based on the Price/Earnings ratio, PATH is valued a bit cheaper than the industry average as 70.14% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.48. PATH is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 41.89, the valuation of PATH can be described as expensive.
PATH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PATH is cheaper than 62.59% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.79, PATH is valued quite expensively.
Industry RankSector Rank
PE 41.98
Fwd PE 41.89

4.2 Price Multiples

PATH's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. PATH is cheaper than 68.35% of the companies in the same industry.
Industry RankSector Rank
P/FCF 43.99
EV/EBITDA N/A

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PATH does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)200.55
PEG (5Y)N/A
EPS Next 2Y13.24%
EPS Next 3Y9.23%

0

5. Dividend

5.1 Amount

No dividends for PATH!.
Industry RankSector Rank
Dividend Yield N/A

UIPATH INC - CLASS A

NYSE:PATH (3/28/2024, 8:04:01 PM)

After market: 22.7096 +0.04 (+0.17%)

22.67

-0.11 (-0.48%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap12.83B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 41.98
Fwd PE 41.89
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)200.55
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.04%
ROE -4.46%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 85.04%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.63
Quick Ratio 3.63
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)260%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y0.21%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)23.58%
Revenue growth 3Y29.12%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y